Introduction
Modem therapeutic regimens produce complete remission in most cases of lymphoblastic leukaemia. In contrast the results so far obtained in acute myeloid leukaemia (A.M.L.) are more disappointing, and thus intensive research is needed in this field. We report here the results of a one-year trial of the Hammersmith Hospital protocol as reported by Spiers (1972) for the treatment of patients with A.M.L.
Material and Methods
Twenty-seven patients were admitted to the trial; 18 were new cases and 9 were already under treatment when the protocol was Departments of Medicine At the time of writing we were unable to evaluate survival in these patients as 10 were still alive. Among the 17 dead the mean survival was 5-2 months; in those still alive, however, this would be appreciably longer, as nine of them were still in complete remission.
SIDE EFFECTS
Treatment was tolerated fairly well by most patients. The most common side effects were nausea and vomiting, leucopenia, alopecia, and facial rashes.
Nausea and vomiting occurred in all patients, at least on the first day of each course of treatment, but could be controlled easily by the administration of metoclopramide. Leucopenia was a major problem, as most of our patients were already leucopenic before the beginning of treatment, and in eight cases the neutrophil count was zero. We therefore decided to treat all patients with hypercellular blastic marrow with six courses of T.R.A.P. irrespective of the leucocyte count. The W.B.C. dropped below 1,000/mm3 in two cases and below 2,000/mm3 in 10; however, only one of these patients died before the end of the induction period, while six patients who were not so severely leucopenic died within the first month of treatment.
When remission was obtained the leucocyte count ranged between 2,000 and 8,000/mm3 in all patients; in four instances he interval between the maintenance courses had to be increased to 16 days because the W.B.C. had dropped below 2,000/mm3.
Alopecia occurred in two cases and a facial rash in one. In no case was cardiotoxicity noticed. However, we administered 0 4 mg deslanoside (Cedilanid) intravenously 30 minutes before the injection of daunorubicin. Deslanoside competes with daunorubicin for the same cardiac receptors, thus decreasing the toxicity of daunorubicin.
Discussion
The short period of observation and the small numbers of treated patients do not permit direct comparison of our results with those previously reported by other workers. The proportion of remissions obtained by us, however, does not differ greatly from those reported by Crowther et al. (1973) with daunorubicin (in double the doses used by us) and cytarabine, by Whitecar et al. (1972) with C.O.A.P., and by Gee et al. (1969) with thioguanine and cytarabine.
It is notable that in our study the incidence of remission in the older patients has been high compared with results from other centres (Crowther et al., 1973) . This difference could be explained by our use of relatively small doses of the more toxic drugs. It is possible that this results in treatment that is better tolerated and more effective in the elderly while at the same time being insufficient for the treatment of some young patients.
One aspect of the results worth noting was the less favourable responses of patients with stem-cell, promyelocytic, and erythroleukaemic types of leukaemia when compared with those with myeloblastic and myelomonocytic disease. Of the 10 patients with the former types of A.M.L. eight were less than 50 years old, so the poorer results in our young patients could be associated with the unequal distribution of the different types of leukaemia with respect to age.
The inclusion of more patients in the trial will allow us to elucidate this point. At present our observations suggest that the dose of daunorubicin should be increased in the younger patients, or at least in those with stem-cell leukaemia.
Our experience suggests that the Hammersmith protocol is especially suitable for the treatment of A.M.L. because it produces a good proportion of remissions with only moderate toxicity to the patient and with only short periods of stay in hospital.
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